- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Complement 3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN)
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Pegcetacoplan – March 2026
Solution for subcutaneous infusion 1,080 mg in 20 mL
Last updated
11 March 2026